These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 25805745)
1. High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis. Schaier M; Scholl C; Scharpf D; Schmitt WH; Schwenger V; Zeier M; Sommerer C Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i138-45. PubMed ID: 25805745 [TBL] [Abstract][Full Text] [Related]
2. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019 [TBL] [Abstract][Full Text] [Related]
4. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611 [TBL] [Abstract][Full Text] [Related]
5. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509 [TBL] [Abstract][Full Text] [Related]
6. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus. Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815 [TBL] [Abstract][Full Text] [Related]
8. Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients. Neuberger M; Sommerer C; Böhnisch S; Metzendorf N; Mehrabi A; Stremmel W; Gotthardt D; Zeier M; Weiss KH; Rupp C Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):543-550. PubMed ID: 31924555 [TBL] [Abstract][Full Text] [Related]
11. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Vethe NT; Bremer S; Rootwelt H; Bergan S Ther Drug Monit; 2008 Dec; 30(6):647-55. PubMed ID: 18806697 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model. Langman LJ; Shapiro AM; Lakey JR; LeGatt DF; Kneteman NM; Yatscoff RW Transplantation; 1996 Jan; 61(1):87-92. PubMed ID: 8560580 [TBL] [Abstract][Full Text] [Related]
15. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients. Thi MT; Mourad M; Capron A; Tshinanu FM; Vincent MF; Wallemacq P Clin Biochem; 2015 Apr; 48(6):401-5. PubMed ID: 25523299 [TBL] [Abstract][Full Text] [Related]
16. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients. Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219 [TBL] [Abstract][Full Text] [Related]
18. Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring. Reine PA; Vethe NT; Kongsgaard UE; Andersen AM; Line PD; Ali AM; Bergan S Scand J Clin Lab Invest; 2013 Mar; 73(2):117-24. PubMed ID: 23281843 [TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic Monitoring of Mycophenolic Acid Therapy: Improved Liquid Chromatography-Tandem Mass Spectrometry Method for Measuring Inosin-5'-Monophosphate Dehydrogenase Activity. Weißbarth G; Wiesen MHJ; Fietz C; Streichert T; Ehren R; Weber LT; Müller C Ther Drug Monit; 2020 Apr; 42(2):282-288. PubMed ID: 31425491 [TBL] [Abstract][Full Text] [Related]
20. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]